These studies combined prompted subsequent clinical evaluation of Vemurafenib against BRAFV600E-mutated gliomas (11) and more recently clinical use of BRAF and MEK inhibitor combination treatment in patients with BRAFV600E-mutated CNS tumors. This evidence concerns the gene MAP2K7 and glioma.